NASDAQ: RGEN · Life Sciences · 7 alerts · CIK 730272
Share price
$162.78Close, Nov 16
Market cap
$10.4B
Shares outstanding
63.92MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Repligen Corp filings on SEC EDGAR ↗
Repligen $1B Debt Financing with U.S. Bank Trust Company, National Association
Repligen Corporation issued $1.0 billion in 0.25% Convertible Senior Notes due 2031. The transaction included $541.4 million issued in exchange for existing 2028 notes and $458.6 million issued for cash to manage the company's debt maturity profile and capital structure.
Repligen reported a net loss of $38.4 million for the third quarter of 2026, primarily driven by a $41.2 million intangible asset impairment charge. Despite the loss, total revenue grew to $209.3 million for the quarter, up from $188.8 million in the prior year period, while cash provided by operating activities increased to $104.2 million for the first nine months of the year.
Repligen Corporation entered into agreements to issue $1.0 billion in 0.25% Convertible Senior Notes due 2031. The transaction includes $541.4 million in notes issued to exchange existing 1.00% notes due 2028 and $458.6 million in notes issued for cash to new investors.
Repligen Corporation reported record third-quarter 2026 revenue of $209.3 million, representing 11% reported and 12.5% organic growth. The company also announced the completion of its BioLife Solutions acquisition in October and raised its full-year 2026 revenue guidance to a range of $844-$852 million.
“We delivered a record third quarter, with $209 million in revenue and 12.5% organic growth, driven by continued strength across our diversified portfolio. End-market demand continues to improve, with healthy trends in consumables and services complemented by a growing capital equipment order book.”
Olivier Loeillot, President and Chief Executive Officer
“The completion of the BioLife acquisition in October marks a significant milestone for Repligen, and integration is progressing well. Early customer feedback has been very encouraging, and we have already taken actions to realize a sizable portion of our expected operating expense synergies. Our strong year-to-date performance, continued order momentum and the addition of BioLife give us confidence to raise our full-year guidance again.”
Olivier Loeillot, President and Chief Executive Officer
Repligen CEO Olivier Loeillot Sells $1.04M of Stock
Olivier Loeillot, CEO, sold 5,535 shares of Repligen Corp at $178.75 to $190.00 a share (average $187.29) in 2 transactions, worth $1.04M in total on Oct 5, 2026. Shares held after the trade: 45,788 (-8.4%).
Repligen Corporation completed its acquisition of BioLife Solutions, Inc., a developer of cell processing tools for the cell and gene therapy market. Under the terms of the merger, BioLife stockholders received $11.25 in cash and 0.1442 shares of Repligen common stock for each share held. The deal expands Repligen's presence in the cell therapy workflow by adding BioLife's biopreservation media portfolio, including the CryoStor product line.
Counterparty
BioLife Solutions, Inc.
“BioLife’s highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market, adding a deeply embedded, high-margin consumables business with attractive recurring revenue. Together, we are better positioned to support customers across critical stages of the cell therapy workflow and help advance the development and commercialization of next-generation therapies.”
Olivier Loeillot, President and Chief Executive Officer of Repligen